Abstract
Resistance to chemoradiotherapy is a major obstacle to a favorable outcome in cancer treatment. Neoadjuvant chemoradiotherapy treatment (nCRT) however, can lead to complete tumor regression in a significant proportion of patients with rectal cancer (up to 40%). Conversely, approximately 60% of patients have only partial or no tumor remission after nCRT. In attempt to identify biological m…